Botox® vs Jeuveau®: Popular FDA-Approved Botulinum Toxin Comparison

✦ Provider Reference

Botox Cosmetic® and Jeuveau® are two botulinum toxin type A products commonly used in aesthetic medicine. Both are FDA-approved for the temporary improvement of glabellar lines and are frequently used off-label by experienced injectors to treat additional dynamic facial wrinkles.

While several botulinum toxin brands are now available—including Dysport®, Xeomin®, Daxxify®, and Letybo®—Botox and Jeuveau are often compared because Jeuveau was introduced specifically for aesthetic use and positioned as a modern alternative to Botox Cosmetic®. In clinical practice, both products produce very similar cosmetic outcomes when appropriate dosing and injection technique are used, although differences in branding, market positioning, and pricing are frequently discussed.

Please note: All brand names are registered trademarks of their respective manufacturers. There is currently no FDA-approved “generic” botulinum toxin type A product.

Read More: A comparison of all six FDA-approved botulinum toxins.

Key Facts About Botox® vs Jeuveau®

  • Both Botox Cosmetic® and Jeuveau® are botulinum toxin type A neuromodulators that temporarily reduce dynamic facial wrinkles by blocking acetylcholine release at the neuromuscular junction.
  • When appropriate dosing and injection technique are used, Botox and Jeuveau generally produce very similar cosmetic outcomes for common treatments such as glabellar frown lines.
  • Unlike Dysport®, Jeuveau dosing units are considered clinically comparable to Botox units, and many injectors use approximately a 1:1 unit conversion when transitioning between the two products.
  • Jeuveau® was developed specifically for aesthetic use and received FDA approval in 2019 for the treatment of glabellar lines, while Botox Cosmetic® has a longer clinical history and multiple FDA-approved aesthetic treatment areas.
  • Botox Cosmetic® remains the most widely recognized neuromodulator brand among patients, while Jeuveau is often positioned as a competitively priced alternative focused exclusively on aesthetic practices.

Botox Cosmetic® and Jeuveau® use similar potency units in clinical practice, and many aesthetic providers treat them as roughly equivalent on a 1:1 dosing basis, although exact dosing may vary by injector preference and treatment area.

Botox® vs Jeuveau® Clinical Comparison

CategoryBotox Cosmetic®Jeuveau®
FDA Approval Year20022019
ManufacturerAllergan / AbbVieEvolus
Active ToxinOnabotulinumtoxinAPrabotulinumtoxinA
Accessory ProteinsPresentPresent
Typical Onset3–5 days3–5 days
Typical Duration3–4 months3–4 months
Conversion Ratio (Jeuveau : Botox)1:1~1:1 (units generally considered comparable in clinical practice)
Primary FDA-Approved Aesthetic UseGlabellar lines, crow’s feet, forehead lines, platysma bandsGlabellar lines
Product PositioningFirst FDA-approved aesthetic botulinum toxin with the longest clinical track recordDeveloped specifically for aesthetic use and marketed as a modern alternative to Botox
StorageRefrigeratedRefrigerated
Immunogenicity RiskVery lowVery low
Approximate Cost per Equivalent Treatment$$$$$–$$$ (often priced competitively vs Botox)
Typical Glabellar Dose20 units20 units

Botox Cosmetic® Overview

Botox Cosmetic® (onabotulinumtoxinA), manufactured by AbbVie/Allergan, is the most established botulinum toxin product used in aesthetic medicine. Botulinum toxin was first approved by the U.S. Food and Drug Administration (FDA) in 1989 for the treatment of facial muscle spasms and other neurologic conditions. As clinicians began using the medication off-label to soften dynamic facial wrinkles during the 1990s, Botox Cosmetic® became the first botulinum toxin type A product to receive FDA approval specifically for aesthetic use.

Initial approval for glabellar frown lines occurred in 2002, followed by approvals for lateral canthal lines (crow’s feet) in 2013, forehead lines in 2017, and platysma bands of the neck in 2024. These approvals made Botox Cosmetic® the first neuromodulator with four separate FDA-approved aesthetic treatment areas.¹ ²

Like other botulinum toxin type A products, Botox works by blocking presynaptic release of acetylcholine at the neuromuscular junction, temporarily weakening targeted facial muscles and reducing the appearance of dynamic wrinkles. Clinical onset typically occurs within three to five days, with maximal effect at approximately two weeks and a typical duration of three to four months for most aesthetic indications.¹

Because of its long clinical history and strong brand recognition, Botox Cosmetic® remains the most widely recognized neuromodulator product worldwide and is often used colloquially as a generic term for cosmetic toxin injections. More than two decades of widespread aesthetic use and over 100 million distributed vials have contributed to its dominant market position.³ Market analyses suggest Botox products continue to hold roughly 60 percent of the U.S. aesthetic toxin market.⁴

Demand for neuromodulator procedures has expanded substantially over the past two decades as minimally invasive cosmetic treatments have become more widely accepted. Millions of injections are performed annually, and the global botulinum toxin market is expected to continue growing as patient demand for non-surgical facial rejuvenation increases.⁵ ⁶ For many aesthetic practices, the strong public familiarity with the Botox brand can make it easier to introduce neuromodulator treatments compared with newer toxin products entering the aesthetic market.

AbbVie also supports Botox Cosmetic® with the Alle℠ loyalty and rewards program, which allows patients to accumulate points for aesthetic treatments and redeem them toward future procedures. The platform can help practices encourage repeat visits and maintain patient engagement with both the brand and their injecting provider.

References

  1. U.S. Food and Drug Administration. BOTOX Cosmetic® (onabotulinumtoxinA) Prescribing Information.
  2. Carruthers A. Treatment of crow’s feet lines and forehead lines with onabotulinumtoxinA. Dermatologic Surgery.
  3. AbbVie. BOTOX Cosmetic® brand information and global usage data.
  4. Botox® market share and industry competition overview.
  5. Aesthetic neurotoxin market size and growth analysis.
  6. Global botulinum toxin market growth projections.

Because Botox Cosmetic® established the early market for aesthetic neuromodulators, newer toxin products such as Jeuveau® are often compared against it as a reference standard when clinicians evaluate treatment options.

Jeuveau® Overview

Jeuveau® (prabotulinumtoxinA), manufactured by Evolus and produced by Daewoong Pharmaceutical, is a botulinum toxin type A product developed specifically for aesthetic medicine. The product received U.S. Food and Drug Administration (FDA) approval in 2019 for the temporary improvement of moderate-to-severe glabellar lines in adult patients.¹ Unlike earlier neuromodulators that were initially approved for therapeutic indications, Jeuveau was designed and positioned from the outset as a cosmetic botulinum toxin treatment.

Like other botulinum toxin type A neuromodulators, Jeuveau works by blocking presynaptic release of acetylcholine at the neuromuscular junction, temporarily weakening facial muscles responsible for dynamic wrinkles. Clinical onset typically occurs within three to five days, with peak effect at approximately two weeks and a typical duration of three to four months for most aesthetic treatments.²

One notable difference often discussed when comparing Jeuveau with Botox Cosmetic® involves dosing equivalence. Unlike Dysport®, whose units differ significantly from Botox units, Jeuveau dosing units are generally considered clinically comparable to Botox units. Many aesthetic providers therefore treat Jeuveau and Botox dosing as roughly equivalent on a 1:1 basis in common treatment areas such as the glabella.

Since its introduction, Jeuveau has been marketed primarily to aesthetic practices and is sometimes referred to informally as “Newtox.” The brand focuses on modern digital marketing strategies and competitive pricing aimed at aesthetic clinics. While Botox Cosmetic® continues to dominate overall market share, Jeuveau has gained traction among practices seeking an alternative neuromodulator with similar clinical performance.

As a newer entrant to the neuromodulator market, Jeuveau does not yet have the same decades-long clinical history as Botox Cosmetic®. However, published clinical trials submitted for FDA approval demonstrated comparable safety and efficacy outcomes for the treatment of glabellar lines.³ As a result, many injectors consider Jeuveau to perform similarly to other botulinum toxin type A products when appropriate dosing and injection technique are used.

References

  1. U.S. Food and Drug Administration. Jeuveau® (prabotulinumtoxinA) Prescribing Information.
  2. Clinical studies evaluating prabotulinumtoxinA for the treatment of glabellar lines.
  3. Hexsel D, et al. Botulinum toxin type A products: clinical comparison and therapeutic equivalence. Dermatologic Therapy.

Frequently Asked Questions: Botox® vs Jeuveau®

Is Jeuveau® the same as Botox®?

Jeuveau® and Botox Cosmetic® are both botulinum toxin type A neuromodulators that temporarily reduce dynamic facial wrinkles by relaxing targeted muscles. Although they use slightly different toxin formulations, clinical results are generally very similar when appropriate dosing and injection technique are used.

Do Jeuveau® and Botox® use the same dosing units?

Unlike Dysport®, which uses different potency units, Jeuveau® units are generally considered clinically comparable to Botox® units. Many aesthetic providers treat dosing between the two products as roughly equivalent on a 1:1 basis, although exact dosing can vary depending on treatment area and injector preference.

Does Jeuveau® work faster than Botox®?

Both products typically begin showing visible results within about three to five days, with maximal improvement usually occurring within two weeks after treatment. Most clinical studies suggest the onset of action is similar between the two neuromodulators.

Does Jeuveau® last as long as Botox®?

For most aesthetic treatments, Jeuveau® and Botox® produce results that last approximately three to four months. Individual patient response, dosing strategy, and treatment area can influence how long results remain visible.

Is Jeuveau® cheaper than Botox®?

Jeuveau® is often priced competitively compared with Botox Cosmetic®. Some aesthetic practices offer Jeuveau treatments at a lower price per unit or per treatment session, although actual pricing varies by clinic and geographic region.

Which is better: Botox® or Jeuveau®?

Neither product is universally better. Botox Cosmetic® has the longest clinical history and the strongest brand recognition among patients, while Jeuveau® was developed specifically for aesthetic use and is sometimes chosen by practices seeking a competitively priced alternative. When used with appropriate technique, both neuromodulators can produce safe and effective cosmetic results.